查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2067787

全球多價疫苗市場規模、佔有率、趨勢和成長分析報告（2026-2034年）

Global Multivalent Vaccines Market Size, Share, Trends & Growth Analysis Report 2026-2034
出版日期: | 出版商: Value Market Research | 英文 326 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

全球多價疫苗市場預計將從2025年的96.9億美元成長至2034年的233億美元，2026年至2034年的複合年成長率（CAGR）為10.24%。隨著醫療衛生系統將高效的疾病預防和全面的免疫策略置於優先地位，該市場正經歷強勁成長。多價疫苗可在單一配方中提供多種病毒株和疾病的保護，從而提高免疫覆蓋率和便利性。感染疾病的傳播和免疫規劃的擴展是市場成長的主要驅動力。政府支持和全球公共衛生舉措也進一步促進了需求成長。

製藥公司正大力投資疫苗研發，以提高疫苗的有效性、安全性和涵蓋疾病範圍。生物技術和免疫學的進步推動了多種病原體的創新疫苗製劑的研發。日益增強的健康意識和不斷擴大的免疫宣傳活動促進了疫苗的廣泛分發。針對兒童和成人的免疫接種力道加大，進一步提振了市場前景。

未來的成長機會預計將源自於疫苗的持續創新和全球醫療保健覆蓋範圍的擴大。針對新興感染疾病的下一代多價疫苗的研發將創造巨大的成長潛力。對生產能力和分銷基礎設施的投資將提高各地區疫苗的供應量。持續關注疾病預防和公共衛生緊急準備將支持市場的長期成長。

我們的報告經過精心撰寫，旨在提供涵蓋廣泛行業和市場的全面且切實可行的洞察。每份報告都包含幾個關鍵組成部分，旨在幫助您全面了解市場環境：

市場概覽：本節對市場進行了清晰的說明，包括關鍵定義、分類以及當前行業格局的概述。

市場動態：對影響市場成長的主要促進因素、限制因素、機會和挑戰進行詳細評估。這包括技術發展、法律規範和不斷變化的行業趨勢等因素。

市場區隔分析：本部分根據產品類型、應用、最終用戶和地區將市場系統性地分類為若干關鍵細分市場。本部分揭示了每個細分市場的表現、成長潛力和市場貢獻。

競爭格局：我們對主要市場參與企業進行了詳細評估，包括其市場定位、產品系列、策略舉措和財務表現。這有助於深入了解競爭趨勢和主要參與者所採取的策略。

市場預測：本部分提供基於數據的市場規模和成長模式預測，預測期為指定時期。它綜合考慮了歷史趨勢、當前市場狀況和定量分析，以識別預期的未來趨勢。

區域分析：這包括對主要地理區域的市場表現進行全面檢驗，確定高成長地區和區域趨勢，以更深入地了解區域市場機會。

新趨勢與新機會：識別關鍵市場趨勢、技術進步和新興投資機會。本部分重點在於潛在成長領域和未來產業趨勢。

客製化選項：我們提供靈活的報告客製化服務，以滿足您的特定需求。這包括額外的細分、國家/地區分析、競爭對手分析、客製化資料點或針對特定細分市場的洞察，從而更有效地支援您的策略決策。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

  • 市場譜系展望
  • 滲透率和成長前景分析
  • 價值鏈分析
  • 法律規範
    • 標準與合規性
    • 監管影響分析
  • 市場動態
    • 市場促進因素
    • 市場限制因素
    • 市場機遇
    • 市場挑戰
  • 波特五力分析
  • PESTLE分析

第4章：全球多價疫苗市場：按類型分類

  • 市場分析、洞察與預測
  • 結合疫苗
  • 去活化疫苗和次單位疫苗
  • 減毒活疫苗
  • 類毒素疫苗
  • 重組疫苗

第5章：全球多價疫苗市場：依疾病分類

  • 市場分析、洞察與預測
  • 流感
  • 肺炎
  • 肝炎
  • 腦膜炎
  • 輪狀病毒

第6章：全球多價疫苗市場：依給藥途徑分類

  • 市場分析、洞察與預測
  • 口服
  • 注射藥物

第7章：全球多價疫苗市場：依年齡層別分類

  • 市場分析、洞察與預測
  • 兒童
  • 成人
  • 老年人

第8章：全球多價疫苗市場：依分銷管道分類

  • 市場分析、洞察與預測
  • 醫院藥房
  • 零售藥房
  • 網路藥房

第9章：全球多價疫苗市場：依地區分類

  • 區域分析
  • 北美市場分析、洞察與預測
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲市場分析、洞察與預測
    • 英國
    • 法國
    • 德國
    • 義大利
    • 俄羅斯
    • 其他歐洲國家
  • 亞太市場分析、洞察與預測
    • 印度
    • 日本
    • 韓國
    • 澳洲
    • 東南亞
    • 其他亞太國家
  • 拉丁美洲市場分析、洞察與預測
    • 巴西
    • 阿根廷
    • 秘魯
    • 智利
    • 其他拉丁美洲國家
  • 中東和非洲市場分析、洞察與預測
    • 沙烏地阿拉伯
    • UAE
    • 以色列
    • 南非
    • 其他中東和非洲國家

第10章 競爭格局

  • 最新趨勢
  • 公司分類
  • 供應鏈和銷售管道合作夥伴（根據現有資訊）
  • 市場佔有率和市場定位分析（基於現有資訊）
  • 供應商情況（基於現有資訊）
  • 策略規劃

第11章：公司簡介

  • 主要公司的市佔率分析
  • 公司簡介
    • Pfizer Inc
    • Merck & Co. Inc
    • Sanofi SA
    • AstraZeneca Plc
    • Abbott Laboratories
    • Novartis AG
    • GlaxoSmithKline Plc
    • Boehringer Ingelheim International GmbH
    • Moderna Inc
    • BioNTech SE
    • Zydus Lifesciences Limited
    • CSL Seqirus
    • Sinovac Biotech Ltd
    • GC Biopharma Corp
    • Emergent BioSolutions Inc
簡介目錄
Product Code: VMR11219358

The global multivalent vaccines market size is expected to reach USD 23.30 Billion in 2034 from USD 9.69 Billion in 2025, growing at a CAGR of 10.24 during 2026-2034.This market is experiencing robust growth as healthcare systems prioritize efficient disease prevention and broad-spectrum immunization strategies. Multivalent vaccines provide protection against multiple strains or diseases within a single formulation, improving vaccination coverage and convenience. Rising prevalence of infectious diseases and increasing immunization programs are major factors driving market expansion. Government support and global public health initiatives are further contributing to demand growth.

Pharmaceutical companies are investing heavily in vaccine research and development to enhance efficacy, safety, and disease coverage. Advances in biotechnology and immunology are enabling the creation of innovative vaccine formulations targeting multiple pathogens. Growing awareness regarding preventive healthcare and expanding vaccination campaigns are supporting widespread adoption. Increasing pediatric and adult immunization efforts are also strengthening market prospects.

Future opportunities are expected to emerge from ongoing vaccine innovation and expanding global healthcare access. Development of next-generation multivalent vaccines for emerging diseases will create substantial growth potential. Investments in manufacturing capacity and distribution infrastructure will improve availability across regions. Long-term market growth will be supported by continued focus on disease prevention and public health preparedness.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Type

  • Conjugate Vaccines
  • Inactivated and Subunit Vaccines
  • Live Attenuated Vaccines
  • Toxoid Vaccines
  • Recombinant Vaccines

By Disease

  • Influenza
  • Pneumonia
  • Hepatitis
  • Meningitis
  • Rotavirus

By Route of Administration

  • Oral
  • Injectable

By Age Group

  • Pediatrics
  • Adults
  • Geriatrics

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

COMPANIES PROFILED

  • Pfizer Inc., Merck & Co. Inc., Sanofi SA, AstraZeneca plc, Abbott Laboratories, Novartis AG, GlaxoSmithKline plc, Boehringer Ingelheim International GmbH, Moderna Inc., BioNTech SE, Zydus Lifesciences Limited, CSL Seqirus, Sinovac Biotech Ltd., GC Biopharma Corp., Emergent BioSolutions Inc.

TABLE OF CONTENTS

Chapter 1. PREFACE

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definition
  • 1.3. Information Procurement
    • 1.3.1 Information Analysis
    • 1.3.2 Market Formulation & Data Visualization
    • 1.3.3 Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

  • 2.1. Market Snapshot
  • 2.2. Segmental Outlook
  • 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

  • 3.1. Market Lineage Outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Value Chain Analysis
  • 3.4. Regulatory Framework
    • 3.4.1 Standards & Compliance
    • 3.4.2 Regulatory Impact Analysis
  • 3.5. Market Dynamics
    • 3.5.1 Market Drivers
    • 3.5.2 Market Restraints
    • 3.5.3 Market Opportunities
    • 3.5.4 Market Challenges
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis

Chapter 4. GLOBAL MULTIVALENT VACCINES MARKET: BY TYPE 2022-2034 (USD MN and Million Doses)

  • 4.1. Market Analysis, Insights and Forecast Type
  • 4.2. Conjugate Vaccines Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
  • 4.3. Inactivated and Subunit Vaccines Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
  • 4.4. Live Attenuated Vaccines Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
  • 4.5. Toxoid Vaccines Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
  • 4.6. Recombinant Vaccines Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)

Chapter 5. GLOBAL MULTIVALENT VACCINES MARKET: BY DISEASE 2022-2034 (USD MN and Million Doses)

  • 5.1. Market Analysis, Insights and Forecast Disease
  • 5.2. Influenza Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
  • 5.3. Pneumonia Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
  • 5.4. Hepatitis Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
  • 5.5. Meningitis Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
  • 5.6. Rotavirus Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)

Chapter 6. GLOBAL MULTIVALENT VACCINES MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN and Million Doses)

  • 6.1. Market Analysis, Insights and Forecast Route Of Administration
  • 6.2. Oral Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
  • 6.3. Injectable Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)

Chapter 7. GLOBAL MULTIVALENT VACCINES MARKET: BY AGE GROUP 2022-2034 (USD MN and Million Doses)

  • 7.1. Market Analysis, Insights and Forecast Age Group
  • 7.2. Pediatrics Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
  • 7.3. Adults Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
  • 7.4. Geriatrics Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)

Chapter 8. GLOBAL MULTIVALENT VACCINES MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN and Million Doses)

  • 8.1. Market Analysis, Insights and Forecast Distribution Channel
  • 8.2. Hospital Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
  • 8.3. Retail Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
  • 8.4. Online Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)

Chapter 9. GLOBAL MULTIVALENT VACCINES MARKET: BY REGION 2022-2034 (USD MN and Million Doses)

  • 9.1. Regional Outlook
  • 9.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
    • 9.2.1 By Type
    • 9.2.2 By Disease
    • 9.2.3 By Route Of Administration
    • 9.2.4 By Age Group
    • 9.2.5 By Distribution Channel
    • 9.2.6 United States
    • 9.2.7 Canada
    • 9.2.8 Mexico
  • 9.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
    • 9.3.1 By Type
    • 9.3.2 By Disease
    • 9.3.3 By Route Of Administration
    • 9.3.4 By Age Group
    • 9.3.5 By Distribution Channel
    • 9.3.6 United Kingdom
    • 9.3.7 France
    • 9.3.8 Germany
    • 9.3.9 Italy
    • 9.3.10 Russia
    • 9.3.11 Rest Of Europe
  • 9.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
    • 9.4.1 By Type
    • 9.4.2 By Disease
    • 9.4.3 By Route Of Administration
    • 9.4.4 By Age Group
    • 9.4.5 By Distribution Channel
    • 9.4.6 India
    • 9.4.7 Japan
    • 9.4.8 South Korea
    • 9.4.9 Australia
    • 9.4.10 South East Asia
    • 9.4.11 Rest Of Asia Pacific
  • 9.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
    • 9.5.1 By Type
    • 9.5.2 By Disease
    • 9.5.3 By Route Of Administration
    • 9.5.4 By Age Group
    • 9.5.5 By Distribution Channel
    • 9.5.6 Brazil
    • 9.5.7 Argentina
    • 9.5.8 Peru
    • 9.5.9 Chile
    • 9.5.10 Rest of Latin America
  • 9.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
    • 9.6.1 By Type
    • 9.6.2 By Disease
    • 9.6.3 By Route Of Administration
    • 9.6.4 By Age Group
    • 9.6.5 By Distribution Channel
    • 9.6.6 Saudi Arabia
    • 9.6.7 UAE
    • 9.6.8 Israel
    • 9.6.9 South Africa
    • 9.6.10 Rest of the Middle East And Africa

Chapter 10. COMPETITIVE LANDSCAPE

  • 10.1. Recent Developments
  • 10.2. Company Categorization
  • 10.3. Supply Chain & Channel Partners (based on availability)
  • 10.4. Market Share & Positioning Analysis (based on availability)
  • 10.5. Vendor Landscape (based on availability)
  • 10.6. Strategy Mapping

Chapter 11. COMPANY PROFILES OF GLOBAL MULTIVALENT VACCINES INDUSTRY

  • 11.1. Top Companies Market Share Analysis
  • 11.2. Company Profiles
    • 11.2.1 Pfizer Inc
    • 11.2.2 Merck & Co. Inc
    • 11.2.3 Sanofi SA
    • 11.2.4 AstraZeneca Plc
    • 11.2.5 Abbott Laboratories
    • 11.2.6 Novartis AG
    • 11.2.7 GlaxoSmithKline Plc
    • 11.2.8 Boehringer Ingelheim International GmbH
    • 11.2.9 Moderna Inc
    • 11.2.10 BioNTech SE
    • 11.2.11 Zydus Lifesciences Limited
    • 11.2.12 CSL Seqirus
    • 11.2.13 Sinovac Biotech Ltd
    • 11.2.14 GC Biopharma Corp
    • 11.2.15 Emergent BioSolutions Inc